

Applicants: Bover Fuentes, et al.
Application Serial No.: 10/539,172
Filing Date: June 14, 2005
Docket No.: 976-25 PCT/US
Page 2

AMENDMENTS TO THE SPECIFICATION

Please insert the sequence listing after the specification but before the listing of claims.

On page 10, after line 32, but before the Examples, please insert the following new paragraph:

--INCORPORATION OF SEQUENCE LISTING

Incorporated herein by reference in its entirety is the Sequence Listing for the application. The Sequence Listing is disclosed on a computer-readable ASCII text file titled, "Sequence.txt", created on December 11, 2008. The Sequence.txt file is 1 kb in size.--

Please delete the paragraph on page 8, lines 13-17, and replace it with the following new paragraph:

In a preferred formulation, the pharmaceutical combinations that include molecules in the A or B pools, are coupled to the immunopotentiating carrier protein by conjugation, or the formation of chimeric proteins. More particularly, inside the A molecules, GnRH analogue peptide with a sequence of pGlu-His-Trp-Ser-Tyr-Pro-Leu-Arg-Pro-Gly (SEQ ID NO: 1).

Applicants: Bover Fuentes, et al.
Application Serial No.: 10/539,172
Filing Date: June 14, 2005
Docket No.: 976-25 PCT/US
Page 3

Please delete the paragraph on page 9, lines 1-7, and replace it with the following new paragraph:

To fulfill antibody response against GnRH, a GnRH analogue peptide, conjugated to a carrier protein (mammal immunocastration vaccine, EPO 959079), is used for immunization. The GnRH analogue peptide (pGlu-His-Trp-Ser-Tyr-Pro-Leu-Arg-Pro-Gly (SEQ ID NO: 1)), and a carrier protein (a Tetanic Toxoid T-helper epitope), were chemically synthesized using two glycine residues as separators, by solid phase method and Boc/Bzl strategy, using “4-methylbenzhydrylamine” (MBH A-0.75 mmol/g, BACHEM, Swiss).